All In Biotech

Drug Trial Radar · NCT04142424

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Last checked: Nov 19, 2026Latest source record: Nov 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Oct 28, 2019

Primary completion

Nov 12, 2021

Study completion Nov 12, 2021

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in male and female subjects of non-childbearing potential in overweight but otherwise healthy subjects, and healthy Chinese and Japanese subjects.

Conditions

  • Metabolic Disorders
  • Non-alcoholic Steatohepatitis

Interventions

  • AZD2693Drug

    Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

  • PlaceboDrug

    Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects experiencing adverse events and serious adverse eventsTime frame: From baseline (Day 1) until Day 112 (Week 16, Final follow-up)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.